Showing results (131-140 of 239) with videos related to

Sort By:
Pageof 24
The Lancet. Oncology|July 12, 2016
Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trialsIrina Ghislain, Efstathios Zikos, Corneel Coens, et al.
Maturitas|July 31, 2026
Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial programJoAnn V Pinkerton, James A Simon, Nick Panay, et al.
Breast (Edinburgh, Scotland)|September 17, 2019
Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patientsFatima Cardoso, Cristian-Silviu Bușoi, Ivana Cattaneo, et al.
Breast (Edinburgh, Scotland)|April 14, 2010
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trialKelly-Anne Phillips, Karin Ribi, Zhuoxin Sun, et al.
Breast Cancer Research and Treatment|November 4, 2010
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trialKelly-Anne Phillips, Julie Aldridge, Karin Ribi, et al.
Breast (Edinburgh, Scotland)|July 23, 2022
Progression-free survival and quality of life in metastatic breast cancer: The patient perspectiveShirley Mertz, Christine Benjamin, Charis Girvalaki, et al.
Nature Clinical Practice. Oncology|October 5, 2006
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts, Fatima Cardoso, Marc Buyse, et al.
Women'S Health (London, England)|July 14, 2026
Elinzanetant for the Treatment of Menopausal Hot Flashes: A Plain Language Review of the OASIS-1-4 Clinical Trial ResultsJoAnn V Pinkerton, Rossella E Nappi, Claudio N Soares, et al.
Breast Cancer Research and Treatment|January 29, 2016
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordanceGiuseppe Viale, Leen Slaets, Femke A de Snoo, et al.
JAMA Oncology|September 25, 2025
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical TrialFatima Cardoso, William Jacot, Sherko Kuemmel, et al.
Pageof 24